Form 4: Soligenix CSO Donini Acquires 100,000 Stock Options

Soligenix Chief Scientific Officer Oreola Donini acquired 100,000 stock options with an exercise price of $1.63, vesting over time.

Summary

• Oreola Donini, Chief Scientific Officer (CSO) of SOLIGENIX, INC. (SNGX), acquired 100,000 derivative securities in the form of stock options.
• The transaction date for this acquisition was December 11, 2025.
• Each option has an exercise price of $1.63.
• The options entitle the holder to purchase 100,000 shares of Soligenix Common Stock.
• The options begin vesting immediately, with 25% of the shares vesting on December 11, 2025.
• The remaining 75% of the shares will vest in 12 equal installments on each three-month anniversary of December 11, 2025.
• The expiration date for these stock options is December 10, 2035.
• Following this transaction, Oreola Donini beneficially owns 100,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a positive event as it aligns management incentives with shareholder value, though it is a routine compensation disclosure.

Positives

• The grant of stock options to the Chief Scientific Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued tenure and contribution from a key executive.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, focusing solely on an executive's stock option grant.

Industry Context

The grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical industries, aiming to attract, retain, and motivate key scientific and management personnel by linking their personal wealth to the company's stock performance. This practice is standard across publicly traded companies, particularly in sectors reliant on long-term research and development outcomes.

Stakeholder Impact

• Shareholders: The grant of options to a CSO can align management's long-term interests with shareholder value creation, potentially leading to better company performance.
• Employees: This transaction is specific to a key executive and does not directly impact the broader employee base, though it reflects the company's compensation strategy for leadership.

Next Steps

• The remaining 75% of the options will vest in 12 equal installments on each three-month anniversary of December 11, 2025.

Key Dates

Keywords

Soligenix, SNGX, Stock Options, Insider Transaction, Executive Compensation, Form 4, Derivative Securities